VIA Pharmaceuticals, Inc. (VIAP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerVIA Pharmaceuticals, Inc. (VIAP) trades at $0.0005. VIA Pharmaceuticals, Inc. is a development stage biotechnology company focused on creating small molecule drugs for cardiovascular and metabolic diseases. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for VIAP: VIAP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
VIA Pharmaceuticals, Inc. (VIAP) Healthcare & Pipeline Overview
VIA Pharmaceuticals, Inc., a development-stage biotech firm, is focused on developing small molecule drugs targeting cardiovascular and metabolic diseases. Their pipeline includes VIA-3196 for dyslipidemia, a DGAT1 inhibitor for type 2 diabetes, and VIA-2291 for atherosclerotic plaque, positioning them in a competitive pharmaceutical landscape.
What Is the Investment Thesis for VIAP?
VIA Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity characteristic of early-stage biotechnology companies. The company's value hinges on the successful development and commercialization of its drug pipeline, particularly VIA-3196, which is Phase-1 ready. Positive clinical trial results for VIA-3196 and the DGAT1 inhibitor could serve as major catalysts, driving significant stock appreciation. The agreements with Hoffman-LaRoche provide validation and potential revenue streams. However, the company faces substantial risks, including clinical trial failures, regulatory hurdles, and the need for additional funding. With a market cap of $0.00B and a negative P/E ratio, the company's valuation is speculative and dependent on future success.
Based on FMP financials and quantitative analysis
VIAP Key Highlights
VIA-3196 is a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist targeting dyslipidemia.
- DGAT1 inhibitor is in pre-clinical development for the treatment of type 2 diabetes.
- VIA-2291, a 5-Lipoxygenase inhibitor, has completed Phase 2 clinical trials for the treatment of atherosclerotic plaque.
- VIA Pharmaceuticals has research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd.
- The company has a Beta of -0.60, indicating a potential inverse correlation with market movements, but this may be unreliable given the company's OTC status and limited trading volume.
Who Are VIAP's Competitors?
VIAP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIAP's Key Strengths?
Proprietary drug candidates targeting significant unmet needs.
- Established partnerships with major pharmaceutical companies.
- Experienced management team with expertise in drug development.
- Focus on underlying causes of cardiovascular and metabolic diseases.
What Are VIAP's Weaknesses?
Early-stage development company with limited financial resources.
- High dependence on successful clinical trial outcomes.
- Limited commercialization capabilities.
- OTC market listing indicates higher risk and lower liquidity.
What Are the Key Risks for VIAP?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for VIA-3196 or other drug candidates.
- Regulatory delays or rejection of drug approvals.
- Competition from established pharmaceutical companies with greater resources.
- Need for additional funding and potential dilution of existing shareholders.
- Intellectual property challenges or patent infringement claims.
What Are VIAP's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Specialized expertise in cardiovascular and metabolic disease drug development.
- Established partnerships with major pharmaceutical companies.
- First-mover advantage in specific therapeutic areas.
What Does VIAP Do?
Founded in 2004 and headquartered in San Francisco, VIA Pharmaceuticals, Inc. is a biotechnology company in the development stage, concentrating on creating innovative treatments for cardiovascular and metabolic diseases. The company's mission is to address the underlying causes of these conditions through a pipeline of small molecule drugs. VIA Pharmaceuticals is actively developing therapies targeting vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. Their lead drug candidate, VIA-3196, is a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist designed to treat dyslipidemia, including high LDL cholesterol, high triglycerides, and elevated Lp(a). Another key program involves a Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, currently in pre-clinical development, aimed at treating type 2 diabetes with potential benefits in weight control and dyslipidemia. VIA-2291, a 5-Lipoxygenase inhibitor, has completed Phase 2 clinical trials for treating atherosclerotic plaque, a primary cause of heart attacks and strokes. VIA Pharmaceuticals has established research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonists and multiple compounds from its preclinical DGAT1 metabolic disorders program.
What Products and Services Does VIAP Offer?
- Develops small molecule drugs for cardiovascular diseases.
- Creates treatments for metabolic diseases.
- Targets vascular inflammation.
- Addresses high cholesterol and high triglycerides.
- Develops therapies for insulin sensitization/diabetes.
- Focuses on atherosclerotic plaque treatment.
How Does VIAP Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks partnerships with larger pharmaceutical companies for commercialization.
- Out-licenses or sells drug candidates to generate revenue.
What Industry Does VIAP Operate In?
VIA Pharmaceuticals operates within the competitive pharmaceutical industry, specifically targeting cardiovascular and metabolic diseases. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical giants and other biotech firms. The market for cardiovascular and metabolic disease treatments is substantial and growing, driven by aging populations and increasing prevalence of these conditions. VIA Pharmaceuticals' success depends on its ability to develop and commercialize innovative therapies that address unmet needs in these markets.
Who Are VIAP's Key Customers?
- Large pharmaceutical companies seeking to expand their product portfolios.
- Patients suffering from cardiovascular and metabolic diseases.
- Healthcare providers prescribing treatments for these conditions.
- Research institutions involved in clinical trials.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
VIA Pharmaceuticals, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Thomas Quertermous. VIAP has traded publicly since 2007.
Key Financial Metrics
Return on equity for VIA Pharmaceuticals, Inc. stands at 64.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
VIA Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
12 transactions · 6 purchases, 0 sales, 6 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
VIAP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
VIAP Latest News
No recent news available for VIAP.
VIAP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VIAP.
Price Targets
Wall Street price target analysis for VIAP.
VIAP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VIAP; grades run from A+ (80-100) to F (below 30).
Leadership: Thomas Quertermous
CEO
Thomas Quertermous serves as the CEO of VIA Pharmaceuticals, Inc. His background likely includes extensive experience in the biotechnology or pharmaceutical industry, with a focus on drug development and management.
Track Record: Given the limited information, it is difficult to assess Thomas Quertermous's specific track record at VIA Pharmaceuticals. However, as CEO, he is responsible for guiding the company's strategic direction, overseeing drug development programs, and securing partnerships and funding. The company's progress in advancing its drug pipeline, including VIA-3196 and the DGAT1 inhibitor, would be key indicators of his leadership.
VIAP OTC Market Information
The OTC Other tier, where VIA Pharmaceuticals trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure, may not meet minimum listing requirements, and are generally considered to be higher risk compared to companies listed on major exchanges like the NYSE or NASDAQ. These companies may be defunct, shell companies, or in financial distress. Investing in OTC Other stocks requires significant due diligence due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in VIA Pharmaceuticals.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- The OTC Other tier designation indicates a higher risk of fraud or manipulation.
- VIA Pharmaceuticals may be subject to delisting or trading suspensions.
- The company's financial stability and ability to continue operations are uncertain.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's intellectual property and patent protection.
- Evaluate the potential market for the company's products or services.
- Determine the company's cash burn rate and funding needs.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC Other stocks.
- Research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd.
- Development of a pipeline of small molecule drugs targeting cardiovascular and metabolic diseases.
- VIA-3196 is a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist.
- Company was founded in 2004.
Common Questions About VIAP (Healthcare)
What do analysts say about VIAP stock?
Given that VIA Pharmaceuticals trades on the OTC market and has a market cap of $0.00B, formal analyst coverage is unlikely.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market stocks carry higher risk.